- Previous Close
0.3882 - Open
0.3800 - Bid 0.3413 x 100
- Ask 0.3478 x 100
- Day's Range
0.3512 - 0.3839 - 52 Week Range
0.3350 - 3.5000 - Volume
127,029 - Avg. Volume
530,534 - Market Cap (intraday)
1.022M - Beta (5Y Monthly) 2.53
- PE Ratio (TTM)
-- - EPS (TTM)
-13.5400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
tnfpharma.comRecent News: TNFA
View More
Performance Overview: TNFA
Trailing total returns as of 3/18/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TNFA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TNFA
View MoreValuation Measures
Market Cap
1.06M
Enterprise Value
-9.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.01%
Return on Equity (ttm)
-142.68%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-28.92M
Diluted EPS (ttm)
-13.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
10.64M
Total Debt/Equity (mrq)
0.11%
Levered Free Cash Flow (ttm)
-4.21M
Company Insights: TNFA
TNFA does not have Company Insights